Edition:
India

Amicus Therapeutics Inc (FOLD.OQ)

FOLD.OQ on NASDAQ Stock Exchange Global Market

9.61USD
20 Nov 2019
Change (% chg)

$-0.15 (-1.54%)
Prev Close
$9.76
Open
$9.69
Day's High
$9.95
Day's Low
$9.51
Volume
1,271,631
Avg. Vol
859,118
52-wk High
$14.61
52-wk Low
$7.11

Latest Key Developments (Source: Significant Developments)

Amicus Therapeutics Prices Underwritten Offering Of Common Stock
Friday, 31 May 2019 

May 30 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS PRICES UNDERWRITTEN OFFERING OF COMMON STOCK.AMICUS THERAPEUTICS - ANNOUNCED PRICING OF AN UNDERWRITTEN OFFERING OF 16,279,070 SHARES OF ITS COMMON STOCK AT $10.75 PER SHARE.  Full Article

Amicus Therapeutics Announces $150 Million Underwritten Public Offering Of Its Common Stock
Thursday, 30 May 2019 

May 29 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.AMICUS THERAPEUTICS INC - COMMENCED A $150 MILLION UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON STOCK.  Full Article

Amicus Therapeutics Inc Files For Potential Mixed Shelf Offering Size Not Disclosed
Thursday, 25 Apr 2019 

April 24 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Amicus Therapeutics Says U.S. FDA Grants Breakthrough Therapy Designation To Co's AT-GAA In Late Onset Pompe Disease
Monday, 25 Feb 2019 

Feb 25 (Reuters) - Amicus Therapeutics Inc ::U.S. FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION (“BTD”) TO AMICUS’ AT-GAA IN LATE ONSET POMPE DISEASE.AMICUS THERAPEUTICS INC - AMICUS CONTINUES TO EXPECT THAT PIVOTAL PROPEL STUDY WILL BE NEEDED TO SUPPORT FULL APPROVAL OF AT-GAA.  Full Article

Amicus Therapeutics Says Daphne Quimi Promoted To Chief Financial Officer
Thursday, 20 Dec 2018 

Dec 19 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS ANNOUNCES EXECUTIVE TEAM UPDATES.AMICUS THERAPEUTICS INC - DAPHNE QUIMI PROMOTED TO CHIEF FINANCIAL OFFICER.AMICUS THERAPEUTICS INC - DAPHNE QUIMI SUCCEEDS CHIP BAIRD.  Full Article

Amicus Therapeutics Inc And Certain Subsidiaries Entered Into Loan Agreement
Tuesday, 25 Sep 2018 

Sept 25 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS INC - ON SEPT 19, CO, CERTAIN SUBSIDIARIES, ENTERED INTO A LOAN AGREEMENT - SEC FILING.AMICUS THERAPEUTICS INC - LOAN AGREEMENT PROVIDES FOR A $150 MILLION SENIOR SECURED TERM LOAN TO BE EXTENDED TO AMICUS ON OR ABOUT CLOSING DATE.AMICUS THERAPEUTICS INC - TERM LOAN MATURES FIVE YEARS FROM DATE OF FIRST CREDIT EXTENSION.  Full Article

Amicus Therapeutics Reports Q2 Loss Per Share Of $0.33
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATES.Q2 LOSS PER SHARE $0.33.Q2 REVENUE $21.3 MILLION VERSUS I/B/E/S VIEW $19.2 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.33 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 GALAFOLD REVENUE $80 MILLION TO $90 MILLION.UPDATING ITS FULL-YEAR 2018 NET CASH SPEND TO $220 TO $250 MILLION.  Full Article

Amicus Therapeutics Expects 2018 Net Cash Spend Of $230 Mln To $260 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS PROVIDES FULL-YEAR 2018 STRATEGIC OUTLOOK AND FINANCIAL GUIDANCE.AMICUS THERAPEUTICS SEES GALAFOLD FY 2018 REVENUE $75 MILLION TO $85 MILLION.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES TOTALED ABOUT $359 MILLION AT DEC 31, 2017.EXPECTS FULL-YEAR 2018 NET CASH SPEND OF BETWEEN $230 MILLION AND $260 MILLION.CURRENT CASH POSITION IS ANTICIPATED TO FUND ONGOING OPERATIONS INTO AT LEAST SECOND HALF OF 2019.FY2018 REVENUE VIEW $88.9 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Amicus Therapeutics Submits New Drug Application To U.S. FDA For Migalastat
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE.AMICUS THERAPEUTICS INC - ‍LOOK FORWARD TO POTENTIAL U.S. APPROVAL OF MIGALASTAT IN 2018​.  Full Article